“The United States depends on China for 95 percent of the key components that are necessary to make our generic drugs, and if China shut the door on exports, within months, our health care system would begin to collapse.” Rosemary Gibson is a national authority on health care policy and patient safety, and the author of “China Rx: Exposing the Risks of America’s Dependence on China for Medicine.” “How come we don’t know that our medicines are being made in China? And this has been going on for a long time, and for years, there was actually zero regulation. How do we outsource production from a country with the highest standards in the world to places with no standards?” she asks. In this episode, we dive into the realities of China’s control of America’s medical supply chain, the increasing problem of contaminated medications, and what the current administration can do to fix it.
We interviewed almost exactly five years
ago. This was COVID pandemic time, early
days. And you were talking about what
this exposed in our supply chains of
components of medicines, the the threat
that existed there. And I was shocked. I
was this this was frankly unbelievable
information to me that we could be so
vulnerable here in the west to China
using these supply chains. Has anything
changed? I remember when we met Yan and
it was as Washington and the country was
shutting down and we talked about China
RX and that's what exposed how dependent
we are as a country on China for what we
need to survive as a country during a
pandemic.
The United States depends on China for
95% of the key
components that are necessary to make
our generic
drugs. And if China shut the door on
exports, within months, our health care
system would begin to collapse. That's
how dependent we are. And it's not just
us. The world is dependent. Europe is
dependent because China has a chokeold
on those upstream raw materials and
chemicals needed to make these active
ingredients which makes a medicine
medicine and that turns into the pills
and vials that that we have and take and
I recall that it's about 91% of the
prescribed medicines in the US are
actually these generics. So this is
massive. It's huge. And whatever
hospital you're in, whether it's all the
bigname hospitals, what they use are
generic drugs and they're about 90 91%
of what's administered and prescribed.
Well, this may be obvious to some of our
viewers. Why is this a problem? Well, as
China X predicted a lot of what happened
that in the event of a natural disaster,
global pandemic or geopolitical event,
the United States will be waiting in
line behind other countries to get vital
medicines to save people's lives. We
have lost our industrial base and during
the pandemic that we had rationing of
vital medicines in this country. It
wasn't called rationing. That would
scare the public. The media didn't call
it
rationing. The euphemism used in the
industry is, "Well, Dr. So and so, well,
we won't be able to deliver those drugs
to you today. They're quote on
allocation," which means they're
actually allocating whatever they have
in certain priority areas. So, we were
rationing drugs in the United States.
And this is because what? And spell it
out for me here. This is why because we
have lost our industrial base to be able
to make the medicines 90% of our
medicine supply. We can't make it
anymore. We can't make antibiotics
anymore in this country from beginning
to end. We can't make penicellin. We
can't make those antibiotics needed to
treat sepsis which can kill you. We
can't make the antibiotics to treat
pneumonia, sexually transmitted
diseases. We offshored that and that's a
risk of huge you know tremendous
national security and if I if I may say
while we were very focused on treating
viral infections what about bacterial
infections and during the pandemic in
the early 1900s what people died of was
not viral infection but bacterial
infections and they died because we
didn't have antibiotics and if you
remember back in March 2020 China said
well if the US doesn't do what we want
we could withhold pulled antibiotics
from the United States. Think of that.
Well, I I think you know I remember when
that happened and I was thinking about
our interview, right? Because this was
basically the case in point. Absolutely
right. We have a system that is
perfectly designed for catastrophic
failure and significant loss of human
life. And that has to change and it's
fixable. This is a man-made problem. You
know, it strikes me there's basically
two dimensions here of the problem,
right? One is, you know, where where
they're being made. So, you know, we
know a lot of them come from India, but
we also know that a very significant
portion of what's made in India, those
components come from China. So, it's
really China. China RX exposed that. And
this was a big shock to me. We all think
of India, which is a great generic
powerhouse, but then you look more
deeply and during uh co pandemic the
Indian government actually came out and
said that we depend and our generic
industry depends on China for 69% of the
components it needs for its industry I
can't think of any other product any
other food commodity whether it's wheat
rice corn or energy supplies that we
have so c allowed to be centralized in a
single country whatever country it is is
a disaster waiting to happen you're
giving me a 95% number just explain to
me how you got there. Sure. Well, first
off, we're talking about thousands of
different raw materials and chemicals
that are used to make our medicines,
generic and branded
drugs. And where I got the
95% figure from is from people who
actually make medicines. They are
pharmaceutical engineers. They are CEOs
of companies. So, I'll tell you a quick
story. So in February of 2020 when a
virus was coming from east to west and
going to hit North America, I was having
dinner with five extraordinary people
who had a combined experience of 150
years in making medicine. So I asked him
this question as you know the entree was
being served. I said, 'So, we're going
to need generic medicines to take care
of very sick people in intensive care
units, emergency
rooms. What percentage of the components
needed to make those medicines are
sourced from
China? And it was 90% 95% 90% 95% 95%.
as we went around the
table. So that's one data point from
people who have to go source from
distributors and they in turn this is
their business. It's what they do. It's
like you're a chef and you know where
all your ingredients come from and who
are the best sources and the country of
origin often of where they're made,
where they're produced. Another data
point is um a wonderfully respected
leader in Europe who ran and a company
that supplied actually generics to our
military. He said that it's about
98% of our generic drugs depend on some
component from China. and another
executive uh from Holland now retired.
He said China
owns that raw material market
globally and even the Europeans are
concerned that what if they decide to
withdraw that talking about this first
dimension right which is where you know
all of these things coming from China
hard to fathom that that could have ever
happened you know after that threat of
withholding during the covid
pandemic what has changed have we been
rushing to bring back those supplies
supply chains, repatriate them to
America in the west or you know friend
shore as they call it perhaps as well.
Overall I think there's been very little
change. Companies have habits of how
they
purchase and they want to purchase the
cheapest
product and we can talk more about this
later and how that system works. But if
you have a focus only on cheap and not
quality and
value, it can really get you into
trouble. Here's how the
antibiotic market how we lost that. Our
last penicellin fermentation
plant China dumped penicellin raw
material on the global market in the mid
2000s. Dumped it means they sold it at a
very low price with the intention of
driving
out US, European and even Indian
producers. And at the end of the
day, China became the dominant global
supplier of penicellin material and then
they raised the price. So I think the
reason that we're not winning on this
yet is because China has a strategy and
it knows exactly the pain points of each
country and each region. And if they see
a move in one direction for an important
product, they can say, "Well, we're
going to dump a product, lower the
price, and that will deter Western
manufacturers from getting back into the
game." Well, and we don't have a
strategy like that.
Let me just qualify this that there's
the strategy is not just commercial.
This is an industrial strategy by a
foreign government to remain dominant in
this sector and as it sees fit to use
that as leverage over any country that
it wants to get what it wants. Well, and
it's very interesting that you mentioned
quality of course because this is the
other dimension. Right. Right. Um we
know all sorts of goods. You know, I had
a a trip to the Neutramax uh production
facility. You know, they make some very
very mostly mostly veterinary drugs, but
also a few things, supplements,
veterinary supplements and uh
supplements for humans. A few as well,
some very interesting
ones. One thing they told me, their
quality chief of quality control told me
is, you know, they would get some large
amount of precursor that would arrive or
large amount of component to make to
make the the supplement, right? And they
said they would notice they had a bar.
It said it had to be 95% pure, but
something would come and be 94% pure.
And what they discovered was that if
they ever accepted that 94% pure when 95
was the benchmark, subsequent shipments
would be even lower in terms of purity,
right? And so they would have they
learned they have to ship back that
entire ton or whatever large amount was
so that people understood no that's our
benchmark. And that's astonishing. I
mean that that itself was an astonishing
realization. So there's there's just
this kind of natural
uh I guess incentive to have cheaper
products or these components come in
never mind nefarious intent which is
from from an enemy country. Right. Well,
another prediction in China RX is that
the FDA would lose control over its
ability to perform its regulatory
functions and ensure a safe supply of
medicines being sold in America. And
that's exactly what's happened. And the
the pace of that, the the decline in
what we're seeing in terms of
quality has just um accelerated. And if
we don't fix this now, we're in deep
trouble. I was uh it was fascinating to
hear in February of actually March of uh
2023,
the then FDA commissioner, Dr. Robert
Caiff, was testifying before House
Appropriations, it was budget season for
the FDA. So, this was the most candid
uh comments from an FDA commissioner
that I've ever heard, and I've been
following this now for 11 years.
He was ex very concerned about the
agency's ability to deal with the
Chinese government and its
manufacturers. He said the agency had
been blocked from traveling to China to
conduct on-site inspections of
manufacturing facilities. That's a very
important part of FDA's regulatory
oversight. They check to see if the
building really exists. That's where the
drugs are being made. that they follow
very strict good manufacturing
practices. So the agency had been
blocked from going. A second concern he
raised is the lack of transparency, lack
of just being forthcoming. So if you're
a manufacturer here in the US, you
provide a lot of information to the FDA
about your product and your process,
your quality control, and that's part of
FDA's due diligence. And Dr. Caleb said,
"China is just not
transparent." And a third point that he
raised was uh something that Congress
had done, which was a good thing to do.
Congress gave FDA $10 million to conduct
what's called unannounced
inspections. So imagine you have friends
coming over for dinner. You say, "Why
don't you come over and on a Saturday
night, you know, next next Saturday
night?" So you probably clean up your
house a little bit and, you know, get
things in order.
That's very different from your friends
popping up, ringing the doorbell, say,
"Hey, we're here for dinner." And they
get to see what your house is like in,
you know, in real life, dayto-day. So
unannounced inspections are those where,
and this happens every day in the United
States, the FDA can come to your
facility 8:30 in the morning and say,
"We're here. We're going to be here for
a week or two, and we're going to take a
really close look and conduct our
inspection." And those are are very very
rigorous. Unannounced inspections are
enable you to see in real time what's
happening. Those have not happened at
all in China which has refused them.